Samsung Bioepis Biosimilar OPUVIZ Enters European Market

Regulatory Pathway and Approval Timeline

Samsung Bioepis launched OPUVIZ 40 mg/mL solution for injection today across European markets, entering the competitive aflibercept biosimilar space with a product referencing Eylea. The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in November 2025, clearing the regulatory hurdle that typically takes 12-18 months for biosimilar applications.

The product enters market availability in Q3 2026, following typical pharmaceutical distribution timelines for newly approved biologics. OPUVIZ becomes the fifth biosimilar in Samsung Bioepis' commercial portfolio, signaling continued investment in biosimilar development despite increasing market saturation.

Manufacturing and Formulation Details

OPUVVIZ launches in both vial and pre-filled syringe presentations, giving healthcare providers flexibility in administration protocols. The 40 mg/mL concentration matches the reference product's specifications, requiring no dose adjustments for patients transitioning from Eylea.

This formulation consistency matters for manufacturing scale-up. I see biosimilar developers facing constant pressure to match reference product quality attributes while maintaining cost competitiveness. The pre-filled syringe option particularly reduces administration complexity in ophthalmology clinics handling high patient volumes.

Commercial Strategy and Market Positioning

Samsung Bioepis commercialized two other biosimilars in Europe earlier this year: BYOOVIZ (ranibizumab) and XBRYK (denosumab). The company operates direct commercialization capabilities in European markets, avoiding partnership or licensing arrangements common among smaller biosimilar developers.

In January 2026, Samsung Bioepis finalized settlement and license agreements with Regeneron and Bayer covering OPUVIZ commercialization across Europe and Rest of World territories. This legal resolution removes patent litigation risk that has delayed or derailed competing biosimilar candidates. The agreement permits market entry before patent expiration in exchange for undisclosed royalties.

"We will work closely with healthcare professionals and payers to facilitate access," said Antonio Rito, Vice President and Head of Europe at Samsung Bioepis.

The Republic of Korea approved the same aflibercept biosimilar under the brand name AFILIVU, providing parallel market validation of manufacturing consistency.

Market Impact Assessment

European aflibercept sales exceeded €2.3 billion in 2025, creating substantial opportunity for cost-competitive biosimilar alternatives. Healthcare systems facing budget pressures increasingly mandate biosimilar prescribing, improving patient access while reducing treatment costs by 30-50% versus reference products.

I expect pricing pressure to intensify as additional aflibercept biosimilars receive approval. Samsung Bioepis benefits from first-mover timing with an established European commercial infrastructure, but sustained market share will require manufacturing efficiency and reliable supply continuity.

M4S TAKE

My take: partnerships only work when both sides bring something the other cannot build quickly. The test is whether the combined offering solves a problem neither could address alone. If it does, this is worth watching.

Simon McLoughlin